Vorasidenib

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

In a perioperative trial, vorasidenib therapy resulted in a reduction of more than 90% in the concentration of the oncometabolite 2- ...

Vorasidenib Is Effective against Low-Grade Gliomas - NCI

The investigational drug vorasidenib substantially slowed the growth of tumors in people with low-grade gliomas that had mutations in the ...

FDA approves vorasidenib for Grade 2 astrocytoma or ...

On August 6, 2024, the Food and Drug Administration approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an isocitrate ...

Fundamental Research Paved the Way for the Development of ...

Vorasidenib is a new promising clinical treatment for gliomas. However, this recent breakthrough in the treatment of brain tumors is only a ...

a new hope or a false promise for patients with low-grade glioma?

On 6 August 2024, the FDA approved vorasidenib, an isocitrate dehydrogenase (IDH) inhibitor, for the treatment of patients of ≥12 years of age ...

Vorasidenib Breaks Through as the First Systemic Therapy for ...

Seema Nagpal, MD, discusses the significance of the FDA approval of vorasidenib for adult and pediatric patients with IDH1/2-mutant glioma.

Vorasidenib: MedlinePlus Drug Information

Vorasidenib: learn about side effects, dosage, special precautions, and more on MedlinePlus.

Vorasidenib: Uses, Interactions, Mechanism of Action - DrugBank

Vorasidenib is a isocitrate dehydrogenase type 1 (IDH1) and 2 (IDH2) inhibitor used to treat Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or ...

Vorasidenib - a promising new drug to treat low-grade gliomas

An international phase 3 clinical trial has shown that vorasidenib can slow disease progression in those diagnosed with low-grade glioma.

Servier's VORANIGO® (vorasidenib) tablets receives FDA approval ...

VORANIGO is available and offers glioma patients the ability to actively manage their disease with the convenience of a once-daily pill.

A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 ...

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

FDA Grants Priority Review for Vorasidenib in IDH-Mutant Diffuse ...

The FDA has accepted and granted priority review for the new drug application for vorasidenib for the treatment of IDH-mutant diffuse glioma ...

First Targeted Therapy for Glioma Headed for FDA Approval

Vorasidenib is an oral penetrant inhibitor that can bypass the blood-brain barrier and thus, deliver a more potent drug. It specifically targets the IDH enzyme, ...

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or ...

A dose-proportional increase in plasma exposure of vorasidenib was observed in patients with glioma at doses of 10–300 mg, and less than dose proportional in ...

VORANIGO® (vorasidenib) | For Grade 2 IDH-Mutant Glioma

VORANIGO (40 mg tablets) is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called ...

INDIGO: Vorasidenib Offers Patients With IDH-Mutant Low-Grade ...

Early use of vorasidenib in patients with IDH-mutant grade 2 glioma significantly reduced the risk of disease progression or death compared ...

Servier Receives Regulatory Filing Acceptances from FDA and EMA ...

If approved, vorasidenib would become a first-in-class targeted therapy for patients with IDH-mutant gliomas and would mark Servier's sixth ...

Vorasidenib Delays Disease Progression or Death in Grade 2 ...

Vorasidenib, an oral dual inhibitor of mutant IDH1/2 enzymes, significantly improved progression-free survival in patients with grade 2 ...

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma - Nature

Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH ...

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Conclusions. In patients with grade 2 IDH-mutant glioma, vorasidenib significantly improved progression-free survival and delayed the time to ...